Study of Out of Specification for Tisagenlecleucel

Clinical trial NCT04094311 · RECRUITING

Trial details

NCT number: NCT04094311
Sponsor: Novartis Pharmaceuticals
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

B-cell Acute Lymphoblastic Leukemia Diffuse Large B-cell Lymphoma

Start date: 2019-11-21
Primary completion: 2027-03-31
Enrollment: 200

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.